Phenpromethamine

Phenpromethamine
Clinical data
Trade names	Vonedrine
Other names	N,β-Dimethylphenethylamine; β,N-Dimethylphenethylamine; N,β-Dimethylbenzeneethanamine; Phenylpropylmethylamine; N-Methyl-2-phenylpropan-1-amine; MPPA; BMMPEA; β-Me-NMPEA; β,N-MePEA
Routes of; administration	Nasal inhaler
Drug class	Norepinephrine–dopamine releasing agent
ATC code	None;
Legal status
Legal status	DE: Anlage I (Authorized scientific use only);
Identifiers
	IUPAC name N-methyl-2-phenylpropan-1-amine;
CAS Number	93-88-9;
PubChem CID	22276;
ChemSpider	21277725;
UNII	7D4542I59V;
CompTox Dashboard (EPA)	DTXSID20861690 ;
ECHA InfoCard	100.257.912
Chemical and physical data
Formula	C10H15N
Molar mass	149.237 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(CNC)C1=CC=CC=C1;
	InChI InChI=1S/C10H15N/c1-9(8-11-2)10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3; Key:AUFSOOYCQYDGES-UHFFFAOYSA-N;
	(verify)

Phenpromethamine (former brand name Vonedrine), also known as N,β-dimethylphenethylamine (MPPA, BMMPEA, β-Me-NMPEA, β,N-MePEA), is a sympathomimetic nasal decongestant of the phenethylamine group. It was previously marketed as a nasal inhaler from 1943 through 1960 but is no longer available. The medication is a stimulant and is banned by the World Anti-Doping Agency. It has been detected in dietary supplements starting in the 2010s.

The drug is a monoamine releasing agent (MRA) similarly to β-phenethylamine, amphetamine, and other phenethylamines. It is the N-methyl derivative of β-methylphenethylamine (BMPEA) and the β-methyl derivative of N-methylphenethylamine (NMPEA). Phenpromethamine is known to act as a norepinephrine–dopamine releasing agent (NDRA), with EC₅₀Tooltip half-maximal effective concentration values of 154 nM for norepinephrine and 574 nM for dopamine in rat brain synaptosomes, whereas serotonin was not reported.